Compare RSF & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RSF | XLO |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 49.8M |
| IPO Year | N/A | 2021 |
| Metric | RSF | XLO |
|---|---|---|
| Price | $14.66 | $7.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | 10.6K | ★ 29.0K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,766,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $168.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 589.88 |
| 52 Week Low | $14.23 | $0.46 |
| 52 Week High | $15.07 | $9.25 |
| Indicator | RSF | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 50.35 | 42.24 |
| Support Level | $14.36 | $7.40 |
| Resistance Level | $14.70 | $8.97 |
| Average True Range (ATR) | 0.07 | 0.40 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 47.06 | 13.11 |
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.